.svg)
Neumirna Therapeutics has been awarded the 2025 Shark Tank Investment Prize by the Epilepsy Foundation, receiving a $200,000 investment from the NeuroImpact Fund. The award recognizes Neumirna’s RNA-based platform as one of the most promising innovations for improving the lives of people with drug-resistant epilepsy.
The award followed a live pitch at the Epilepsy Therapies and Diagnostics Development (ETDD) Symposium in Leesburg, Virginia. Neumirna’s CEO, Dr. Janine Erler, presented our platform to a panel of leading clinical experts, industry executives, and investors.
The Epilepsy Foundation’s Shark Tank Competition highlights transformative ideas in treatment, care, and community impact. This year, the program introduced a dual-award structure, offering both a Community Award and an Investment Prize. Neumirna was selected for the top-tier investment category, reflecting broad recognition of its potential to shift the treatment landscape for epilepsy.
Fueling Our Next Phase
This investment will specifically support the safety work required to include people of childbearing potential in future clinical development. It’s a key milestone on our path to building a treatment that is safe, effective, and accessible for all people with drug-resistant epilepsy.
